Clinical trials: Mild-to-moderate Essential Hypertension
Hypertension
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
CYT006-AngQb is a vaccine that induces a B-cell mediated immune response characterized by the generation of specific antibodies (IgG and IgM) against Angiotensin II. The vaccine is administered by subcutaneous injection.
- Trial name
- NCT00701649
- Testing
- CYT006-AngQb
- Where
- 6 sites in Germany, Switzerland
- Volunteers
- 60 people
- Sponsor
- Cytos Biotechnology AG
Essential Hypertension, Renal Impairment
Olmesartan Medoxomil in Hypertension and Renal Impairment
This is a study in hypertensive patients with mild to moderate renal impairment. The antihypertensive efficacy of olmesartan medoxomil is compared to losartan.
- Trial name
- NCT00151827
- Testing
- Olmesartan medoxomil, Losartan, Furosemide oral tablets
- Where
- Germany
- Volunteers
- 393 people
- Sponsor
- Sankyo Pharma Gmbh
Essential Hypertension
Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
- Trial name
- OSCAR (NCT00139698)
- Testing
- olmesartan alone or in combination with hydrochlorothiazide
- Where
- 32 sites in Colombia, Ecuador and 8 more
- Volunteers
- 410 people
- Sponsor
- Pfizer
Essential Hypertension
Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension
The primary aim of the study is to assess the antihypertensive efficacy of SPH3127 in patients with mild to moderate essential hypertension.
- Trial name
- NCT05359068
- Testing
- SPH3127 tablet, Valsartan
- Where
- 40 sites in China
- Volunteers
- 957 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension
LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension
This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.
- Trial name
- NCT01373086
- Testing
- LFF269, Eplerenone
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
This study will evaluate the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension
- Trial name
- NCT00413049
- Testing
- Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg
- Where
- 12 sites in China
- Volunteers
- 698 people
- Sponsor
- Novartis
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Essential Hypertension
Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
To evaluate the efficacy of Amlodipine-Folic Acid Tablets on reduction of blood pressure and plasma total homocysteine.
- Trial name
- NCT01956786
- Testing
- Amlodipine-FA tablet,low dose group, Amlodipine-FA tablet,high dose group, Amlodipine
- Where
- 3 sites in China
- Volunteers
- 540 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Hypertension
Antihypertensive Efficacy and Tolerability and Determine the Adequate Antihypertensive Dosage of Fimasartan in Mild to Moderate Essential Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and tolerability of 8 week treatment with Fimasartan (BR-A-657-K) 20, 60, 120, 240 mg and placebo in patients with mild to moderate essential hypertension and…
- Trial name
- NCT00923611
- Testing
- Fimasartan
- Where
- South Korea
- Volunteers
- 182 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922441
- Testing
- Fimasartan 60 mg group, Fimasartan 120 mg group, Reference (Valsartan 80 mg) group
- Volunteers
- 92 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
BACKGROUND The effects of ACE-inhibitors on fibrinolysis are well documented. Experimental and clinical studies have shown that ACE inhibitors induce a reduction in plasma PAI-1 levels in many cardiovascular diseases, like…
- Trial name
- NCT00644475
- Testing
- Imidapril, Candesartan
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Pavia
Hypertension
The Clinical Study to Evaluate the Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension
The purpose of this clinical study is to evaluate and compare the efficacy and safety of Fimasartan (60mg / 120mg) with Candesartan(8mg) in patients with mild to moderate hypertension.
- Trial name
- NCT01135212
- Testing
- Fimasartan 60mg, Fimasartan 120mg, Candesartan cilexetil
- Where
- South Korea
- Volunteers
- 290 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Comparison of the Antihypertensive Efficacy of Valsartan and Enalapril After Missing One Dose
This study was designed in order to evaluate the blood pressure lowering effect of valsartan compared to enalapril over 24 hours after skipping one daily dose.
- Trial name
- NCT00302705
- Testing
- Valsartan, Enalapril, Ambulatory blood pressure monitoring, Missing one dose
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- University of Vigo
Essential Hypertension
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
The purpose of this study was to evaluate the dose-response relationships of azilsartan, once daily (QD) in participants with mild to moderate uncomplicated essential hypertension.
- Trial name
- NCT01289132
- Testing
- Azilsartan, Candesartan cilexetil
- Volunteers
- 926 people
- Sponsor
- Takeda
Essential Hypertension
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
- Trial name
- NCT00856271
- Testing
- olmesartan medoxomil, losartan potassium
- Where
- 5 sites in China
- Volunteers
- 287 people
- Sponsor
- Daiichi Sankyo
Hypertension
Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension
This is a multi-center, open-label, observational study. The aim of this study is to evaluate the efficacy of Nifedipine GITS on lowering blood pressure in Chinese adults with mild-to-moderate hypertension.
- Trial name
- NCT02641821
- Testing
- Nifedipine GITS
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Peking University First Hospital
Essential,Hypertension
Fimasartan Achieving SBP Target (FAST) Study
The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension.
- Trial name
- FAST (NCT02495324)
- Testing
- Fimasartan, Valsartan, Olmesartan medoxomil
- Where
- 8 sites in South Korea
- Volunteers
- 369 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Obesity, Hypertension
A Study of Efficacy and Safety of Topiramate in the Treatment of Obese Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to compare the efficacy and safety of daily topiramate (96mg or 192mg) versus placebo in obese patients with mild to moderate high blood pressure.
- Trial name
- NCT00236665
- Testing
- topiramate
- Volunteers
- 531 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mild-to-moderate Essential Hypertension
A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients
SYH9056 tablets are a combination of valsartan and levamlodipine maleate. This is a multicenter, randomized, double-blind, parallel-controlled phase III study, designed to validate the efficacy and safety of SYH9056 tablets in…
- Trial name
- NCT06771245
- Testing
- SYH9056, Levamlodipine, Valsartan
- Volunteers
- 606 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.